An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Study Identifier
GMA-LUM-12-021
CT.gov Identifier
NCT01881126
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • bimatoprost 0.01%
  • travatan 0.004%
  • timolol 0.5%
  • hypromellose 0.3%
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Ocular hypertension or glaucoma that requires treatment with medication * Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
    Exclusion Criteria:
    * History of LASIK, LASEK, RK, and/or PRK in the study eye(s) * History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months * Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study

    Protocol Summary

    This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

    Study Locations

    Location
    Status
    Location
    Barrie, Ontario, Canada
    Status
    Not applicable
    Location
    Toronto, Ontario, Canada
    Status
    Not applicable